This In Vitro Diagnostics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The in-vitro diagnostics market size has grown rapidly in recent years. It will grow from $130.74 billion in 2024 to $149.01 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The growth in the historic period can be attributed to the development of automated analyzers and molecular diagnostics, aging population, disease outbreaks, healthcare regulations, personalized medicine.
The in-vitro diagnostics market size is expected to see rapid growth in the next few years. It will grow to $232.69 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to precision medicine, point-of-care testing, digital health and data analytics, pandemic preparedness. Major trends in the forecast period include technological advancements, digital health integration, personalized diagnostics, home testing kits, molecular diagnostics.
The growing adoption of self-administered test kits is set to fuel the expansion of the in vitro diagnostics market in the forthcoming years. These kits are designed for self-use, eliminating the necessity for medical professionals or trained individuals to conduct the tests, allowing people to perform diagnostic evaluations at their residences. This increased accessibility and convenience could potentially result in a higher demand for testing, especially for conditions that may have previously gone undetected. For example, statistics from the Centers for Disease Control and Prevention in April 2022 exhibited a significant surge in the use of at-home COVID-19 tests among adults aged 18 and older in the United States. Comparing the Delta-dominant period (August to December 2021) to the Omicron-dominant period (December to March 2022), there was a notable increase in at-home test utilization among respondents experiencing symptoms resembling COVID-19, rising from 5.7% to 20.1%. Hence, the increasing adoption of self-administered test kits is anticipated to be a driving factor in the growth of the in vitro diagnostics market.
The projected rise in the prevalence of cancer is expected to drive the expansion of the in vitro diagnostics market. Cancer comprises a wide array of over 100 diseases that can manifest in various parts of the body, characterized by the uncontrolled proliferation and dissemination of cells. In vitro diagnostics (IVDs) encompass tests or medical devices that analyze samples obtained from the human body, providing vital information for the screening, diagnosis, and treatment of cancer. For instance, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, projected that there would be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States for the year 2023. Consequently, the anticipated rise in cancer prevalence is set to drive the growth of the in vitro diagnostics market.
Key companies in the in vitro diagnostics market are focusing on the development of innovative products to drive their market growth, such as the Cobas pulse system. This system is a professional blood glucose management solution equipped with mobile digital health capabilities to enhance patient care. For example, in January 2022, Roche Diagnostics, a US-based company specializing in innovative products and services addressing disease prevention, diagnosis, monitoring, screening, and treatment, introduced the Cobas pulse system. This portable device comprises an automated glucose test strip reader, a camera, and a touchscreen for capturing additional diagnostic data. Its user-friendly interface is designed for seamless integration, providing convenient functionalities that optimize processes, save time, and improve operational workflows.
Major players in the in vitro diagnostics (IVD) market are incorporating advanced technologies, such as UIMG image technology and 2D decoder chips, to enhance diagnostic accuracy and efficiency, improve data analysis, optimize workflows, and ultimately deliver better patient outcomes. UIMG image technology is an advanced imaging technique used in diagnostics to capture and analyze high-resolution images, enhancing the visualization and interpretation of biological samples. For example, in November 2023, Newland, a Netherlands-based technology company in the EMEA region, launched a new IVD product line. This product line includes five barcode scanners that are compact, durable, and designed to optimize automated diagnostic processes, aiming to boost diagnostic speed and accuracy in response to the growing demand for efficient healthcare solutions.
Major companies operating in the in vitro diagnostics market include Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories Inc., bioMérieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Crop., Natera Inc., Invitae Crop., Veracyte Inc.
In vitro diagnostics (IVD) are tests performed on biological samples, such as blood, tissue, or urine, collected from the human body to identify diseases, conditions, or infections. Conducted outside the body in controlled environments like laboratories, these tests utilize specialized equipment and reagents. IVDs play a vital role in diagnosing various health conditions, guiding treatment decisions, and monitoring patient health over time.
The principal categories of in-vitro diagnostics equipment encompass point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices and equipment, and immunohematology diagnostic devices and equipment. Hematology instruments, for instance, are machines designed to analyze blood samples, perform blood counts, detect proteins or enzymes, and aid in the diagnosis of diseases or genetic defects. These devices and equipment are used in both public and private settings and involve instruments/equipment as well as disposables. The end-users for these tools include hospitals and clinics, diagnostic laboratories, and other relevant institutions.
The in-vitro diagnostics devices and equipment market research report is one of a series of new reports that provides in-vitro diagnostics devices and equipment market statistics, including in-vitro diagnostics devices and equipment industry global market size, regional shares, competitors with an in-vitro diagnostics devices and equipment market share, detailed in-vitro diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics devices and equipment industry. This in-vitro diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the global in-vitro diagnostics market in 2024. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in-vitro diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the in vitro diagnostics market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The in-vitro diagnostics market size has grown rapidly in recent years. It will grow from $130.74 billion in 2024 to $149.01 billion in 2025 at a compound annual growth rate (CAGR) of 14%. The growth in the historic period can be attributed to the development of automated analyzers and molecular diagnostics, aging population, disease outbreaks, healthcare regulations, personalized medicine.
The in-vitro diagnostics market size is expected to see rapid growth in the next few years. It will grow to $232.69 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to precision medicine, point-of-care testing, digital health and data analytics, pandemic preparedness. Major trends in the forecast period include technological advancements, digital health integration, personalized diagnostics, home testing kits, molecular diagnostics.
The growing adoption of self-administered test kits is set to fuel the expansion of the in vitro diagnostics market in the forthcoming years. These kits are designed for self-use, eliminating the necessity for medical professionals or trained individuals to conduct the tests, allowing people to perform diagnostic evaluations at their residences. This increased accessibility and convenience could potentially result in a higher demand for testing, especially for conditions that may have previously gone undetected. For example, statistics from the Centers for Disease Control and Prevention in April 2022 exhibited a significant surge in the use of at-home COVID-19 tests among adults aged 18 and older in the United States. Comparing the Delta-dominant period (August to December 2021) to the Omicron-dominant period (December to March 2022), there was a notable increase in at-home test utilization among respondents experiencing symptoms resembling COVID-19, rising from 5.7% to 20.1%. Hence, the increasing adoption of self-administered test kits is anticipated to be a driving factor in the growth of the in vitro diagnostics market.
The projected rise in the prevalence of cancer is expected to drive the expansion of the in vitro diagnostics market. Cancer comprises a wide array of over 100 diseases that can manifest in various parts of the body, characterized by the uncontrolled proliferation and dissemination of cells. In vitro diagnostics (IVDs) encompass tests or medical devices that analyze samples obtained from the human body, providing vital information for the screening, diagnosis, and treatment of cancer. For instance, in January 2023, the National Center for Biotechnology Information, a US-based intergovernmental organization, projected that there would be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States for the year 2023. Consequently, the anticipated rise in cancer prevalence is set to drive the growth of the in vitro diagnostics market.
Key companies in the in vitro diagnostics market are focusing on the development of innovative products to drive their market growth, such as the Cobas pulse system. This system is a professional blood glucose management solution equipped with mobile digital health capabilities to enhance patient care. For example, in January 2022, Roche Diagnostics, a US-based company specializing in innovative products and services addressing disease prevention, diagnosis, monitoring, screening, and treatment, introduced the Cobas pulse system. This portable device comprises an automated glucose test strip reader, a camera, and a touchscreen for capturing additional diagnostic data. Its user-friendly interface is designed for seamless integration, providing convenient functionalities that optimize processes, save time, and improve operational workflows.
Major players in the in vitro diagnostics (IVD) market are incorporating advanced technologies, such as UIMG image technology and 2D decoder chips, to enhance diagnostic accuracy and efficiency, improve data analysis, optimize workflows, and ultimately deliver better patient outcomes. UIMG image technology is an advanced imaging technique used in diagnostics to capture and analyze high-resolution images, enhancing the visualization and interpretation of biological samples. For example, in November 2023, Newland, a Netherlands-based technology company in the EMEA region, launched a new IVD product line. This product line includes five barcode scanners that are compact, durable, and designed to optimize automated diagnostic processes, aiming to boost diagnostic speed and accuracy in response to the growing demand for efficient healthcare solutions.
Major companies operating in the in vitro diagnostics market include Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Alere Inc., Arkray Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories Inc., bioMérieux SA, Grifols SA, Hologic Inc., Werfen SA, Laboratory Corporation, Luminex Corporation, Ortho Clinical Diagnostics, PerkinElmer Inc., Qiagen NV, Quest Diagnostics Inc., QuidelOrtho Corporation, Sysmex Corporation, Illumina Inc., Menarini Silicon Biosystems SPA, SpeeDx Pty. Ltd., GENSPEED Biotech GmbH, Accelerate Diagnostics Inc., Merck KGaA, Caris Life Sciences Inc., Bio-Techne Corporation, Myriad Genetics Inc., Genomic Health Inc., Exact Sciences Crop., Natera Inc., Invitae Crop., Veracyte Inc.
In vitro diagnostics (IVD) are tests performed on biological samples, such as blood, tissue, or urine, collected from the human body to identify diseases, conditions, or infections. Conducted outside the body in controlled environments like laboratories, these tests utilize specialized equipment and reagents. IVDs play a vital role in diagnosing various health conditions, guiding treatment decisions, and monitoring patient health over time.
The principal categories of in-vitro diagnostics equipment encompass point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices and equipment, and immunohematology diagnostic devices and equipment. Hematology instruments, for instance, are machines designed to analyze blood samples, perform blood counts, detect proteins or enzymes, and aid in the diagnosis of diseases or genetic defects. These devices and equipment are used in both public and private settings and involve instruments/equipment as well as disposables. The end-users for these tools include hospitals and clinics, diagnostic laboratories, and other relevant institutions.
The in-vitro diagnostics devices and equipment market research report is one of a series of new reports that provides in-vitro diagnostics devices and equipment market statistics, including in-vitro diagnostics devices and equipment industry global market size, regional shares, competitors with an in-vitro diagnostics devices and equipment market share, detailed in-vitro diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics devices and equipment industry. This in-vitro diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the global in-vitro diagnostics market in 2024. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in-vitro diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the in vitro diagnostics market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Executive Summary
in Vitro Diagnostics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on in vitro diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for in vitro diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The in vitro diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Point-of-Care Diagnostics Devices and Equipment; Immunochemistry Diagnostic Devices and Equipment; Clinical Chemistry Diagnostics Devices and Equipment; Molecular Diagnostics Devices and Equipment; Microbiology Diagnostic Devices and Equipment; Hemostasis Diagnostic Devices and Equipment; Hematology Diagnostic Devices and Equipment; Immunohematology Diagnostic Devices and Equipment2) By End User: Hospitals and Clinics; Diagnostic Laboratories; Other End Users
3) By Type of Expenditure: Public; Private
4) By Product: Instruments/Equipment; Disposables
Subsegments:
1) By Point-of-Care Diagnostics Devices and Equipment: Blood Glucose Monitoring; Pregnancy and Fertility Testing; Infectious Disease Testing; Cardiac Markers Testing; Coagulation Testing2) By Immunochemistry Diagnostic Devices and Equipment: Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA); Western Blot; Immunofluorescence Assay; Chemiluminescence Immunoassay (CLIA)
3) By Clinical Chemistry Diagnostic Devices and Equipment: Blood Glucose Testing; Cholesterol Testing; Liver Function Testing; Kidney Function Testing; Electrolyte Testing
4) By Molecular Diagnostics Devices and Equipment: PCR (Polymerase Chain Reaction) Instruments; Next-Generation Sequencing (NGS) Instruments; Microarray Instruments; FISH (Fluorescence in Situ Hybridization) Devices
5) By Microbiology Diagnostic Devices and Equipment: Microbial Culture Systems; Automated Identification Systems; Antimicrobial Susceptibility Testing Systems; Blood Culture Systems
6) By Hemostasis Diagnostic Devices and Equipment: Coagulation Analyzers; Thromboelastography Systems; Platelet Function Analyzers; Clotting Factor Analyzers
7) By Hematology Diagnostic Devices and Equipment: Hematology Analyzers; Hemoglobin Testing Systems; Complete Blood Count (CBC) Devices; Blood Cell Counters
8) By Immunohematology Diagnostic Devices and Equipment: Blood Typing Systems; Crossmatching Systems; Antibody Screening Systems; Blood Bank Analyzers
Key Companies Mentioned: Siemens Healthineers; F. Hoffmann-La Roche AG; Danaher Corporation; Abbott Laboratories Inc.; Thermo Fisher Scientific Inc.
Countries: Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this In Vitro Diagnostics market report include:- Siemens Healthineers
- F. Hoffmann-La Roche AG
- Danaher Corporation
- Abbott Laboratories Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Alere Inc.
- Arkray Inc.
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories Inc.
- bioMérieux SA
- Grifols SA
- Hologic Inc.
- Werfen SA
- Laboratory Corporation
- Luminex Corporation
- Ortho Clinical Diagnostics
- PerkinElmer Inc.
- Qiagen NV
- Quest Diagnostics Inc.
- QuidelOrtho Corporation
- Sysmex Corporation
- Illumina Inc.
- Menarini Silicon Biosystems SPA
- SpeeDx Pty. Ltd.
- GENSPEED Biotech GmbH
- Accelerate Diagnostics Inc.
- Merck KGaA
- Caris Life Sciences Inc.
- Bio-Techne Corporation
- Myriad Genetics Inc.
- Genomic Health Inc.
- Exact Sciences Crop.
- Natera Inc.
- Invitae Crop.
- Veracyte Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 400 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 149.01 Billion |
| Forecasted Market Value ( USD | $ 232.69 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 37 |
